-
PRME Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Prime Medicine (PRME)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 196.54 mm | 196.54 mm | 196.54 mm | 196.54 mm | 196.54 mm | 196.54 mm |
Cash burn (monthly) | (no burn) | (no burn) | 14.74 mm | 16.87 mm | (no burn) | 10.24 mm |
Cash used (since last report) | n/a | n/a | 31.23 mm | 35.75 mm | n/a | 21.69 mm |
Cash remaining | n/a | n/a | 165.31 mm | 160.79 mm | n/a | 174.85 mm |
Runway (months of cash) | n/a | n/a | 11.2 | 9.5 | n/a | 17.1 |
13F holders | Current |
---|---|
Total holders | 133 |
Opened positions | 33 |
Closed positions | 19 |
Increased positions | 39 |
Reduced positions | 32 |
13F shares | Current |
---|---|
Total value | 167.05 bn |
Total shares | 112.67 mm |
Total puts | 172.90 k |
Total calls | 42.60 k |
Total put/call ratio | 4.1 |
Largest owners | Shares | Value |
---|---|---|
ARCH Venture Fund XII | 15.46 mm | $49.46 mm |
GOOG Alphabet | 15.06 mm | $43.98 bn |
GV 2019 | 15.06 mm | $120.95 mm |
ARCH Venture Fund X | 12.26 mm | $0.00 |
Newpath Partners | 6.11 mm | $17.28 mm |
ARK Investment Management | 5.15 mm | $15.04 bn |
BlackRock | 4.52 mm | $13.21 bn |
T. Rowe Price Investment Management | 3.98 mm | $11.62 mm |
FMR | 3.80 mm | $11.10 bn |
Vanguard | 3.66 mm | $10.67 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Feb 25 | Allan Reine | Stock Option Common Stock | Grant | Acquire A | No | No | 2.42 | 275,000 | 665.50 k | 275,000 |
27 Feb 25 | Richard Brudnick | Stock Option Common Stock | Grant | Acquire A | No | No | 2.42 | 225,000 | 544.50 k | 225,000 |
27 Feb 25 | Ann L. Lee | Stock Option Common Stock | Grant | Acquire A | No | No | 2.42 | 275,000 | 665.50 k | 275,000 |
27 Feb 25 | Jeremy Duffield | Stock Option Common Stock | Grant | Acquire A | No | No | 2.42 | 275,000 | 665.50 k | 275,000 |
27 Feb 25 | Meredith Goldwasser | Stock Option Common Stock | Grant | Acquire A | No | No | 2.42 | 90,500 | 219.01 k | 90,500 |